CA2884121C - Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof - Google Patents

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof Download PDF

Info

Publication number
CA2884121C
CA2884121C CA2884121A CA2884121A CA2884121C CA 2884121 C CA2884121 C CA 2884121C CA 2884121 A CA2884121 A CA 2884121A CA 2884121 A CA2884121 A CA 2884121A CA 2884121 C CA2884121 C CA 2884121C
Authority
CA
Canada
Prior art keywords
seq
peptide
trem
use according
tlt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884121A
Other languages
English (en)
French (fr)
Other versions
CA2884121A1 (en
Inventor
Sebastien Gibot
Amir BOUFENZER
Hafid Ait-Oufella
Marc Derive
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National Polytechnique de Lorraine
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National Polytechnique de Lorraine
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National Polytechnique de Lorraine, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National Polytechnique de Lorraine
Publication of CA2884121A1 publication Critical patent/CA2884121A1/en
Application granted granted Critical
Publication of CA2884121C publication Critical patent/CA2884121C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2884121A 2012-09-07 2013-09-09 Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof Active CA2884121C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306079.0 2012-09-07
EP12306079 2012-09-07
PCT/EP2013/068628 WO2014037565A2 (en) 2012-09-07 2013-09-09 Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof

Publications (2)

Publication Number Publication Date
CA2884121A1 CA2884121A1 (en) 2014-03-13
CA2884121C true CA2884121C (en) 2021-10-12

Family

ID=46826397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884121A Active CA2884121C (en) 2012-09-07 2013-09-09 Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof

Country Status (24)

Country Link
US (1) US9657081B2 (https=)
EP (1) EP2892920B1 (https=)
JP (1) JP6307080B2 (https=)
KR (1) KR102181384B1 (https=)
CN (1) CN104837865B (https=)
AU (1) AU2013311606B2 (https=)
CA (1) CA2884121C (https=)
CY (1) CY1123014T1 (https=)
DK (1) DK2892920T3 (https=)
ES (1) ES2797625T3 (https=)
HR (1) HRP20200875T8 (https=)
HU (1) HUE051557T2 (https=)
IL (1) IL237615B (https=)
LT (1) LT2892920T (https=)
MX (1) MX385794B (https=)
NZ (1) NZ705899A (https=)
PL (1) PL2892920T3 (https=)
PT (1) PT2892920T (https=)
RS (1) RS60421B1 (https=)
RU (1) RU2672341C2 (https=)
SI (1) SI2892920T1 (https=)
SM (1) SMT202000309T1 (https=)
WO (1) WO2014037565A2 (https=)
ZA (1) ZA201501779B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US11685785B2 (en) * 2015-06-12 2023-06-27 Ascendo Biotechnology, Inc. Methods and antibodies for modulation of immunoresponse
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
WO2021105137A1 (en) 2019-11-25 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
EP4161551A1 (en) * 2020-06-05 2023-04-12 Inotrem Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection
MX2022016548A (es) 2020-06-26 2023-03-14 Amgen Inc Muteínas de il-10 y proteínas de fusión de las mismas.
US20240173376A1 (en) 2021-03-12 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of marfan syndrome
EP4359441A1 (en) 2021-06-25 2024-05-01 Amgen Inc. Treatment of cardiovascular disease with trem-1 antigen binding proteins
WO2025196177A1 (en) 2024-03-21 2025-09-25 Institut National de la Santé et de la Recherche Médicale Use of soluble trem-1 as a biomarker for assessing the risk of cardiovascular disease in asymptomatic subjects

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
MX9701720A (es) 1994-09-12 1997-06-28 Schering Ag Proceso para la fabricacion de una palidipina modificada, inhibidora de la agregacion plaquetaria inducida por colageno.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1311547A2 (en) * 2000-08-22 2003-05-21 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
GB0426146D0 (en) * 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US7553936B2 (en) * 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
US20100306863A1 (en) 2007-07-23 2010-12-02 Bioxell S.P.A. Screening, therapy and diagnosis
DE102009018620A1 (de) 2009-04-27 2010-10-28 Carefusion Germany 234 Gmbh Ansteuer- und Auswerteschaltung, Messgerät sowie Verfahren zum Messen der Konzentration eines Gases
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
HUE050815T2 (hu) * 2010-04-08 2021-01-28 Inst Nat Sante Rech Med A trem-szerû 1. transzkriptumból (tlt-1) származó gátló peptidek és azok felhasználása

Also Published As

Publication number Publication date
US9657081B2 (en) 2017-05-23
EP2892920A2 (en) 2015-07-15
CN104837865B (zh) 2019-09-24
SMT202000309T1 (it) 2020-07-08
RU2672341C2 (ru) 2018-11-14
HUE051557T2 (hu) 2021-03-01
JP6307080B2 (ja) 2018-04-04
KR20150110460A (ko) 2015-10-02
MX2015002994A (es) 2016-01-14
WO2014037565A9 (en) 2015-06-11
LT2892920T (lt) 2020-07-10
IL237615B (en) 2018-12-31
SI2892920T1 (sl) 2020-08-31
ZA201501779B (en) 2016-10-26
CA2884121A1 (en) 2014-03-13
HRP20200875T1 (hr) 2020-09-04
EP2892920B1 (en) 2020-03-04
US20150232531A1 (en) 2015-08-20
JP2015533791A (ja) 2015-11-26
AU2013311606B2 (en) 2017-10-05
RU2015112625A (ru) 2016-10-27
KR102181384B1 (ko) 2020-11-20
WO2014037565A2 (en) 2014-03-13
PT2892920T (pt) 2020-06-16
CN104837865A (zh) 2015-08-12
WO2014037565A3 (en) 2014-05-15
HRP20200875T8 (hr) 2021-04-30
PL2892920T3 (pl) 2020-08-24
AU2013311606A1 (en) 2015-04-09
DK2892920T3 (da) 2020-06-08
NZ705899A (en) 2018-08-31
MX385794B (es) 2025-03-18
ES2797625T3 (es) 2020-12-03
CY1123014T1 (el) 2021-10-29
HK1212360A1 (en) 2016-06-10
IL237615A0 (en) 2015-04-30
RS60421B1 (sr) 2020-07-31

Similar Documents

Publication Publication Date Title
CA2884121C (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
JP5918750B2 (ja) Trem様転写物1(tlt−1)から誘導された阻害性ペプチドおよびその使用
ES2477498T3 (es) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular
Wesche-Soldato et al. The role and regulation of apoptosis in sepsis
WO2013190014A1 (en) Improved cd31 peptides
US7959918B2 (en) Methods for treating vascular disease
US20240226306A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
HK1212360B (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
AU2006301494A1 (en) Antagonists against interaction of PF4 and RANTES
US20120076754A1 (en) Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
CN117835998A (zh) 促凝血肽及其应用
JP2023516163A (ja) 組成物及び方法
WO2016060158A1 (ja) 細胞障害抑制剤、前記細胞障害抑制剤を含む低酸素血症によって生じる臓器障害の予防又は治療用医薬組成物、及び前記細胞障害抑制剤を含む虚血性脳血管障害の予防又は治療用医薬組成物
AU2015202354A1 (en) Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240909

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204